Jeffrey W. Taub MD

Pediatric Hematology & Oncology•Detroit, MI

Division Chief of Oncology, Professor of Pediatrics, Children's Hosp of Michigan, Wayne State Univer

Join to View Full Profile

Childrens Hospital of Michigan3901 Beaubien BLVD CardiologyDetroit, MI 48201
Phone+1 313-745-5835
Fax+1 313-993-0894

Summary

Jeffrey Taub, MD, based in Detroit, MI, is a specialist in Pediatric Hematology & Oncology with education from the University of Western Ontario and training at DMC Children's Hospital of Michigan. His expertise includes lymphoma and leukemia. He has a substantial publication record in respected journals such as Blood, Cancer Research, Clinical Cancer Research, Biochemical Pharmacology, Leukemia, & Pediatric Blood & Cancer, covering topics from pharmacogenomics to acute leukemia treatments. Dr. Taub has served as a Principal Investigator in multiple clinical trials focusing on acute myeloid leukemia and other hematological conditions. He has received extramural grant funding from multiple sources including the NCI/NIH adn Leukemia and Lymphoma Society. Recognized for his contributions, he has received honors including the Regional Top Doctor from Castle Connolly and is a Fellow of the American Academy of Pediatrics.

Education & Training

Children's Hospital of MichiganFellowship, Pediatric Hematology/Oncology, 1994
DMC Children's Hospital of Michigan1991
University of Western OntarioMD, Medicine, 1983 - 1987
University of Western OntarioClass of 1987

Certifications & Licensure

MI State Medical License 1988 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Super Doctor SuperDoctors.com
Fellow (FAAP) American Academy of Pediatrics

Clinical Trials

Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Start of enrollment: 2007 Mar 01
Completed
Phase 3
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder Start of enrollment: 2006 Mar 01
Withdrawn
Phase 3
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2008 Aug 04
Completed
Phase 3
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies Start of enrollment: 2008 Jul 17
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Start of enrollment: 2009 Jul 13
Active, not recruiting
Phase 3
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
ACTIVE_NOT_RECRUITING
PHASE3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
ACTIVE_NOT_RECRUITING
PHASE3
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET) Start of enrollment: 2011 Feb 01
Unknown status
Not Applicable
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
ACTIVE_NOT_RECRUITING
PHASE3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission Start of enrollment: 2012 Feb 21
ACTIVE_NOT_RECRUITING
PHASE3
Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial Start of enrollment: 2012 Feb 01
Completed
Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder Start of enrollment: 2012 Feb 01
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Start of enrollment: 2017 Mar 29
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

The G.O.A.T. Diagnosis: A Rare and Uncommon Diagnosis of Macrocytic Anemia.
Gianna G Valenti, Hannah Greenberg, Süreyya Savaşan, Jeffrey W Taub
Clinical Pediatrics. 2025-02-01
ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress.
Jenna L Carter, Yongwei Su, Eman T Al-Antary, Jianlei Zhao, Xinan Qiao
Journal of Experimental & Clinical Cancer Research. 2025-01-09
The evolution and history of Vinca alkaloids: From the Big Bang to the treatment of pediatric acute leukemia.
Jeffrey W Taub, Steven A Buck, Ana C Xavier, Holly Edwards, Larry H Matherly
Pediatric Blood & Cancer. 2024-11-01

Abstracts/Posters

High-Dose Cytarabine Is Indispensable for the Survival of Children with Myeloid Leukemia of Down Syndrome Despite Negative Minimal Residual Disease Post-Induction
Jeffrey W. Taub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML
Jeffrey W. Taub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Combination of CUDC-907 and Gilteritinib Shows Promising Antileukemic Activity in Vitro and In Vivo in Preclinical Models of FLT3-ITD AML
Jeffrey W. Taub, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced By the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Novel Therapy for FLT3-ITD Acute Myeloid Leukemia Utilizing the Combination of CUDC-907 and Gilteritinib
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Biomedical Engineer and Quality Assurance Expert, Jeffrey P. Taub, Joins NDA Partners as Expert ConsultantMay 27th, 2020
‘Those on the Front Lines of Cancer’ to Air on PBSOctober 3rd, 2019
A High-Throughput Screen Indicates Gemcitabine and JAK Inhibitors May Be Useful for Treating Pediatric AMLMay 16th, 2019
Join now to see all

Grant Support

Enhancing treatments for myeloid leukemia associated with Down syndromeWAYNE STATE UNIVERSITY2024–2028
The paradox of myeloid leukemia of Down syndromeWAYNE STATE UNIVERSITY2023–2025
Molecular And Pharmacologic Correletes Of Acute Myeloid Leukemia In DOWN SyndromeNational Cancer Institute2007–2011
Cystathionine B Synthase And ARA C Therapy For LeukemiaNational Cancer Institute2001–2005